Ifosfamide and Doxorubicin Combination Chemotherapy for Recurrent Nasopharyngeal Carcinoma Patients |
Dede, Didem Sener
(Department of Medical Oncology, Hacettepe University Faculty of Medicine)
Aksoy, Sercan (Department of Medical Oncology, Hacettepe University Faculty of Medicine) Cengiz, Mustafa (Department of Radiation Oncology, Hacettepe University Faculty of Medicine) Gullu, Ibrahim (Department of Medical Oncology, Hacettepe University Faculty of Medicine) Altundag, Kadri (Department of Medical Oncology, Hacettepe University Faculty of Medicine) |
1 | Altundag K, Aksoy S, Gullu I, et al (2004). Salvage ifosfamidedoxorubicin chemotherapy in patients with recurrent nasopharyngeal carcinoma pretreated with Cisplatin-based chemotherapy. Med Oncol, 21, 211-5. DOI |
2 | Au E, Ang PT (1994). A phase II trial of 5-fluorouracil and cisplatinum in recurrent or metastatic nasopharyngeal carcinoma. Ann Oncol, 5, 87-9. DOI |
3 | Azli N, Fandi A, Bachouchi M, et al (1995). Final report of a phase II study of chemotherapy with bleomycin, epirubicin, and cisplatin for locally advanced and metastatic/recurrent undifferentiated carcinoma of the nasopharyngeal type. Cancer J Sci Am, 1, 222-9. |
4 | Boussen H, Cvitkovic E, Wendling JL, et al (1991). Chemotherapy of metastatic and/or recurrent undifferentiated nasopharyngeal carcinoma with cisplatin, bleomycin, and fluorouracil. J Clin Oncol, 9, 1675-81. DOI |
5 | Chan AT, Grégoire V, Lefebvre JL, et al (2010). Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 21, 187-9. DOI |
6 | Chan ATC, Ma B, Tung S, et al (2007). Biweekly gemcitabine and oxaliplatin (GEMOX) in first-line metastatic or recurrent nasopharyngeal carcinoma (NPC) an early report. J Clin Oncol Proc Am Soc Clin Oncol, 25, 6071. |
7 | Chua DT, Kwong DLW, Sham JS, et al (2000). A phase II study of ifosfamide, 5-fluorouracil and leucovorin in patients with recurrent nasopharyngeal carcinoma previously treated with platinum chemotherapy. Eur J Cancer, 36, 736-41. DOI |
8 | Chua DT, Sham JS, Au GK, et al (2003). A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy. Oral Oncol, 39, 361-6. DOI |
9 | Chua DT, Sham JS, Au GK, et al (2005). A phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma. Oral Oncol, 41, 589-95. DOI |
10 | Fong KW, Chua EJ, Chua ET, et al (1996). Patient profile and survival in 270 computer tomography-staged patients with nasopharyngeal cancer treated at the Singapore general hospital. Ann Acad Med Singapore, 25, 341-6. |
11 | Foo KF, Tan EH, Leong SS, et al (2002). Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type. Ann Oncol, 13, 150-6. DOI |
12 | Guo Y, Glisson BS (2010). Systemic treatment for incurable recurrent and/or metastatic nasopharyngeal carcinoma. In 'Nasopharyngeal cancer multidisciplinary management. Eds Lu JJ, Cooper JS and Lee AWM. Springer -Verlag Berlin Heidelberg, pp 267-75. |
13 | Ma BB, Hui EP, Chan AT, et al (2008). Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions. Cancer Sci, 99, 1311-8. DOI |
14 | Hasbini A, Mahjoubi R, Fandi A, et al (1999). Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type. Ann Oncol, 10, 421-5. DOI |
15 | Huang HQ, Zhou ZM, Li YH, et al (2002). Preliminary results of ifosfamide and doxorubicin regimen in treatment of patients with recurrent and metastatic nasopharyngeal carcinoma. Ai Zheng, 21, 409-11. |
16 | Leong SS, Wee J, Tay MH (2005). Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: a phase II trial using a triplet combination. Cancer, 103, 569-75. DOI |
17 | Ma BB, Tannock IF, Pond GR et al (2002). Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma. Cancer, 95, 2516-23. DOI |
18 | McCarthy JS, Tannock IF, Degendorfer P, et al (2002). A phase II trial of docetaxel and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. Oral Oncol, 38, 686-90. DOI |
19 | Ngan RK, Yiu HH, Lau WH, et al (2002). Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study. Ann Oncol, 13, 1252-8. DOI ScienceOn |
20 | Onat H, Basaran M, Esassolak, et al (2002). High-dose epirubicin and cisplatin in locally advanced undifferentiated nasopharyngeal carcinoma. Clin Oncol, 14, 449-54. DOI |
21 | Perez CA, Devineni VR, Marcial-Vega V, et al(1992). Carcinoma of the nasopharynx: factors affecting prognosis. Int J Radiat Oncol Biol Phys, 23, 271-80. DOI |
22 | Wang J, Li J, Hong X, et al (2008). Retrospective case series of gemcitabine plus cisplatin in the treatment of recurrent and metastatic nasopharyngeal carcinoma. Oral Oncol, 44, 464-70. DOI ScienceOn |
23 | Razak AR, Siu LL, Liu FF et al (2010). Nasopharyngeal carcinoma: the next challenges. Eur J Cancer, 46, 1967-78. DOI |
24 | Siu LL, Czaykowski PM, Tannock IF, et al (1998). Phase I/II study of the CAPABLE regimen for patients with poorly differentiated carcinoma of the nasopharynx. J Clin Oncol, 16, 2514-21. DOI |
25 | Taamma A, Fandi A, Azli N, et al (1999). Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type. Cancer, 86, 1101-8. DOI |
26 | Wei KR, Yu YL, Yang YY, et al (2010). Epidemiological trendsof nasopharyngeal carcinoma in China. Asian Pac J Cancer Prev, 11, 29-32. |
27 | Wei K, Xu Y, Liu J, et al (2010). No incidence trends and no change inpathological proportions of nasopharyngeal carcinoma in Zhongshan in 1970-2007. Asian Pac J Cancer Prev, 11,1595-9. |
28 | Yeo W, Leung TW, Chan AT, et al (1998). A phase II study combination of paclitaxel and carboplatin in advanced nasopharyngeal carcinoma. Eur J Cancer, 34, 2027-31. DOI |
![]() |